RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence

Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype with few therapy options besides chemotherapy. Although platinum-based drugs have shown initial activity in BRCA1-mutated TNBCs, chemoresistance remains a challenge. Here we show that RAD6B (UBE2B), a principal mediator of t...

Full description

Saved in:
Bibliographic Details
Published in:Biochim Biophys Acta Mol Basis Dis
Main Authors: Haynes, Brittany, Gajan, Ambikai, Nangia-Makker, Pratima, Shekhar, Malathy P.
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6896319/
https://ncbi.nlm.nih.gov/pubmed/31639439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbadis.2019.165561
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items